Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-10

Clinical Trial Update: A Study of Zanubrutinib in Patients With ITP [Phase 2]

View source ↗

Summary

Phase 2 trial update of Zanubrutinib in immune thrombocytopenia (ITP) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia, Bruton Tyrosine Kinase | Phase 2 | Status: COMPLETED